Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / ADXN
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Addex Therapeutics Ltd. ADXN

8 fiscal years on record · CHF · FY2024 reported · SEC filings only
CHF 404,102
▼ 74.9% YoY
CHF 7.1M
CHF -5.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Through December 31, 2025 it had raised an aggregate of CHF 356.6 million in equity financing and generated an aggregate of CHF 66.8 million in revenue, applied to the discovery and development of its pipeline of drug candidates. Its lead development compound is dipraglurant, a metabotropic glutamate receptor subtype 5 negative allosteric modulator under evaluation in post-stroke and traumatic brain injury recovery. A second development compound, ADX71149, is an orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator. Indivior has licensed worldwide rights to the GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates. Under the terms of that agreement the company selected a compound to advance its own independent GABAB PAM program for the treatment of chronic cough. It holds a 20% equity interest in the spin out company Neurosterix US Holdings LLC, which develops preclinical stage drug candidates for schizophrenia and mood disorders. The company has worked exclusively on allosteric modulation drug discovery and development since its inception in 2002.

Written from the business description in Addex Therapeutics Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 15 May 2026. Every sentence was checked against that document before publication.

Growth

CHF 404,102.00
Revenue, FY2024 · full 8-year series below
Revenue CHF M Net income CHF M
FY2024 · Revenue 0.4 · Net income 7.1
2.5M5.0M-10.0M-20.0M
2017202020232024
Compound annual growth
−48.3%
−31.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −31.9% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -681.8% · Net ·
-200%-400%-600%
201720202024
ROE
FY2024 · ROE 130.4%
50%100%-100%-200%-300%
201720202024
Three returns, three denominators.
Gross margin·
Operating margin-681.8%
Net margin·
EBITDA·

Each CHF of equity produced 130 cents of profit this year.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow CHF M
FY2024 · FCF -5.4
-10M-20M
201720202024
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsCHF 10.7M
CashCHF 3.3M
Current ratio4.42×

Not available: we don't have the total debt figure for this period.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · CHF

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ADXN, 8-year financial record
Metric 20242023202220212020201920182017
Revenue CHF B0.00.00.00.00.00.00.0◌
Operating income CHF B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA CHF B◌◌◌◌◌◌◌◌
Income tax CHF B0.00.00.00.00.00.00.0◌
Net income CHF B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow CHF B−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0
EPS, diluted CHF 0.07−0.14−0.46−0.45−0.48−0.56◌◌
Dividend / sh CHF ◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %130.4−348.5−190.5−97.3−64.1−45.6−8.1−244.3
Shares out B0.130.130.080.040.030.030.030.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

Addex Therapeutics Ltd.vsAC Immune SASame industry: Pharmaceutical PreparationsAddex Therapeutics Ltd.vsMindMaze Therapeutics Holding SASame industry: Pharmaceutical Preparations
More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 28 reconciliationsAUDITED

Reconciled in 8 of the 8 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code V8
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image